Treatment
thrombocytopenia, PD, Neutropenia, neutropenia
NEUTROPENIA, ADVERSE EVENTS, THROMBOCYTOPENIA, ADVERSE EVENT, NEUTROPENIA
The median duration of therapy was 3.5 cycles for RP (range, 1-15 cycles) and 4 cycles for P (range, 1-12 cycles). Dose reductions occurred in 12 patients in the RP group (16.4%) and 8 patients in the P group (10.7%). Neutropenia and thrombocytopenia were the most prominent adverse events leading to cycle delay and dose reduction in the RP and P groups. The most common adverse event leading to dose reduction in the RP group was neutropenia. The main reason for therapy discontinuation was PD in both groups.